One study did investigate efficacy in the context of using celeboxib to prevent colorectal adenoma and found carriage of CYP2C9*3, but not CYP2C9*2, was associated with increased protection against adenoma in those taking high doses though the overall effect was small [140]. Here, CYP2C9 is linked to adenoma.